Advertisement
NRSN Новости Форекс
NeuroSense Says Phase 2b ALS Trial Meets Primary And Secondary Endpoints
NeuroSense Therapeutics Ltd. (NRSN) announced Tuesday that it met its primary safety and tolerability endpoints and achieved secondary clinical efficacy endpoints in the top-line results of its 6-month, randomized, placebo-controlled, double-blind segment the Company's Phase 2b amyotrophic lateral sclerosis (ALS) trial of PrimeC (PARADIGM).
RTTNews
|
630 дней спустя
